器官移植术后淋巴组织增生性疾病的临床回顾性研究

刘彦权; 胡晓梅; 殷悦; 林霖; 沈建箴; 陈玉婷; 唐焕文

doi:10.19401/j.cnki.1007-3639.2022.07.009

您当前的位置：

首页 >

文章列表页 >

器官移植术后淋巴组织增生性疾病的临床回顾性研究

个案报道 | 更新时间：2025-12-31

- 器官移植术后淋巴组织增生性疾病的临床回顾性研究
- A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder
- 中国癌症杂志 2022年32卷第7期页码：650-656
- 作者机构：
  
  1. 广东医科大学研究生院第一临床医学院血液内科,广东东莞 523808
  2. 广东省东莞市环境医学重点实验室,广东东莞 523808
  3. 福建医科大学附属协和医院病理科,福建福州 350001
  4. 福建医科大学附属协和医院血液病研究所,福建福州 350001
  5. 福建医科大学附属协和医院影像科,福建福州 350001
- 作者简介：
  
  [ "刘彦权（ORCID: 0000-0001-6826-0456）,博士,主治医师,E-mail: doctorliuyanquan@163.com。" ]
  唐焕文（ORCID: 0000-0003-1632-2103）,博士,教授、博士研究生导师,广东医科大学研究生院院长,E-mail: thw@gdmu.edu.cn。
- 基金信息：
  
  国家自然科学基金面上项目(82073582);广东省教育厅高校特色创新项目(2020KTSCX048);广东医科大学学科建设项目(4SG22003G);广东医科大学学科建设项目(4SG21209G);广东医科大学科技创新专项计划(4SG22046G)
- DOI：10.19401/j.cnki.1007-3639.2022.07.009
  中图分类号： R733.4
- 收稿：2022-03-26，
  
  纸质出版：2022-07-30
- 稿件说明：
移动端阅览
刘彦权, 胡晓梅, 殷悦, 等. 器官移植术后淋巴组织增生性疾病的临床回顾性研究[J]. 中国癌症杂志, 2022,32(7):650-656.

Yanquan LIU, Xiaomei HU, Yue YIN, et al. A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder[J]. China Oncology, 2022, 32(7): 650-656.
刘彦权, 胡晓梅, 殷悦, 等. 器官移植术后淋巴组织增生性疾病的临床回顾性研究[J]. 中国癌症杂志, 2022,32(7):650-656. DOI： 10.19401/j.cnki.1007-3639.2022.07.009.

Yanquan LIU, Xiaomei HU, Yue YIN, et al. A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder[J]. China Oncology, 2022, 32(7): 650-656. DOI： 10.19401/j.cnki.1007-3639.2022.07.009.

摘要

Abstract

关键词

Keywords

references

LAU E , MOYERS J T , WANG B C , et al . Analysis of post-transplant lymphoproliferative disorder (PTLD) outcomes with Epstein-Barr virus (EBV) assessments-a single tertiary referral center experience and review of literature [J ] . Cancers (Basel) , 2021 , 13 ( 4 ): 899.

SWERDLOW S H , CAMPO E , PILERI S A , et al . The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J ] . Blood , 2016 , 127 ( 20 ): 2375 - 2390 . DOI: 10.1182/blood-2016-01-643569 http://doi.org/10.1182/blood-2016-01-643569 https://ashpublications.org/blood/article/127/20/2375/35286/The-2016-revision-of-the-World-Health-Organization https://ashpublications.org/blood/article/127/20/2375/35286/The-2016-revision-of-the-World-Health-Organization

STYCZYNSKI J , VAN DER VELDEN W , FOX C P , et al . Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines [J ] . Haematologica , 2016 , 101 ( 7 ): 803 - 811 . DOI: 10.3324/haematol.2016.144428 http://doi.org/10.3324/haematol.2016.144428 http://www.haematologica.org/cgi/doi/10.3324/haematol.2016.144428 http://www.haematologica.org/cgi/doi/10.3324/haematol.2016.144428

SCHIEFER A I , SALZER E , FÜREDER A , et al . PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: an inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories [J ] . Cancer Med , 2019 , 8 ( 10 ): 4656 - 4668 . DOI: 10.1002/cam4.2394 http://doi.org/10.1002/cam4.2394 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2394 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2394

PETRARA M R , GIUNCO S , SERRAINO D , et al . Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment [J ] . Cancer Lett , 2015 , 369 ( 1 ): 37 - 44 . DOI: 10.1016/j.canlet.2015.08.007 http://doi.org/10.1016/j.canlet.2015.08.007 https://linkinghub.elsevier.com/retrieve/pii/S0304383515005364 https://linkinghub.elsevier.com/retrieve/pii/S0304383515005364

OPELZ G , HENDERSON R . Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients [J ] . Lancet , 1993 , 342 ( 8886/8887 ): 1514 - 1516 . DOI: 10.1016/S0140-6736(05)80084-4 http://doi.org/10.1016/S0140-6736(05)80084-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673605800844 https://linkinghub.elsevier.com/retrieve/pii/S0140673605800844

COCKFIELD S M . Identifying the patient at risk for post-transplant lymphoproliferative disorder [J ] . Transpl Infect Dis , 2001 , 3 ( 2 ): 70 - 78 . DOI: 10.1034/j.1399-3062.2001.003002070.x http://doi.org/10.1034/j.1399-3062.2001.003002070.x http://doi.wiley.com/10.1034/j.1399-3062.2001.003002070.x http://doi.wiley.com/10.1034/j.1399-3062.2001.003002070.x

OPELZ G , DÖHLER B . Lymphomas after solid organ transplantation: a collaborative transplant study report [J ] . Am J Transplant , 2004 , 4 ( 2 ): 222 - 230 . DOI: 10.1046/j.1600-6143.2003.00325.x http://doi.org/10.1046/j.1600-6143.2003.00325.x http://doi.wiley.com/10.1046/j.1600-6143.2003.00325.x http://doi.wiley.com/10.1046/j.1600-6143.2003.00325.x

WISTINGHAUSEN B , GROSS T G , BOLLARD C . Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients [J ] . Pediatr Hematol Oncol , 2013 , 30 ( 6 ): 520 - 531 . DOI: 10.3109/08880018.2013.798844 http://doi.org/10.3109/08880018.2013.798844 https://www.tandfonline.com/doi/full/10.3109/08880018.2013.798844 https://www.tandfonline.com/doi/full/10.3109/08880018.2013.798844

UHLIN M , WIKELL H , SUNDIN M , et al . Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation [J ] . Haematologica , 2014 , 99 ( 2 ): 346 - 352 . DOI: 10.3324/haematol.2013.087338 http://doi.org/10.3324/haematol.2013.087338 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.087338 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.087338

NAKANISHI C , KAWAGISHI N , SEKIGUCHI S , et al . Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience [J ] . Surg Today , 2012 , 42 ( 8 ): 741 - 751 . DOI: 10.1007/s00595-012-0127-7 http://doi.org/10.1007/s00595-012-0127-7 http://link.springer.com/10.1007/s00595-012-0127-7 http://link.springer.com/10.1007/s00595-012-0127-7

STYCZYNSKI J , GIL L , TRIDELLO G , et al . Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working party of the European group for blood and marrow transplantation [J ] . Clin Infect Dis , 2013 , 57 ( 6 ): 794 - 802 . DOI: 10.1093/cid/cit391 http://doi.org/10.1093/cid/cit391 https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cit391 https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cit391

DIERICKX D , HABERMANN T M . Post-transplantation lymphoproliferative disorders in adults [J ] . N Engl J Med , 2018 , 378 ( 6 ): 549 - 562 . DOI: 10.1056/NEJMra1702693 http://doi.org/10.1056/NEJMra1702693 http://www.nejm.org/doi/10.1056/NEJMra1702693 http://www.nejm.org/doi/10.1056/NEJMra1702693

LUSKIN M R , HEIL D S , TAN K S , et al . The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder [J ] . Am J Transplant , 2015 , 15 ( 10 ): 2665 - 2673 . DOI: 10.1111/ajt.13324 http://doi.org/10.1111/ajt.13324 https://onlinelibrary.wiley.com/doi/10.1111/ajt.13324 https://onlinelibrary.wiley.com/doi/10.1111/ajt.13324

DESTEFANO C B , DESAI S H , SHENOY A G , et al . Management of post-transplant lymphoproliferative disorders [J ] . Br J Haematol , 2018 , 182 ( 3 ): 330 - 343 . DOI: 10.1111/bjh.15263 http://doi.org/10.1111/bjh.15263 https://onlinelibrary.wiley.com/doi/10.1111/bjh.15263 https://onlinelibrary.wiley.com/doi/10.1111/bjh.15263

MALONEY E M , BUSQUE V A , HUI S T , et al . Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder [J ] . JCI Insight , 2020 , 5 ( 6 ): 131644.

GULLEY M L , TANG W H . Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder [J ] . Clin Microbiol Rev , 2010 , 23 ( 2 ): 350 - 366 . DOI: 10.1128/CMR.00006-09 http://doi.org/10.1128/CMR.00006-09 https://journals.asm.org/doi/10.1128/CMR.00006-09 https://journals.asm.org/doi/10.1128/CMR.00006-09

中华医学会器官移植学分会 . 器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版) [J ] . 器官移植 , 2019 , 10 ( 2 ): 149 - 157 .

Branch of Organ Transplantation of Chinese Medical Association . Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China (2019 edition) [J ] . Organ Transplant , 2019 , 10 ( 2 ): 149 - 157 .

KANAKRY J A , HEGDE A M , DURAND C M , et al . The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases [J ] . Blood , 2016 , 127 ( 16 ): 2007 - 2017 . DOI: 10.1182/blood-2015-09-672030 http://doi.org/10.1182/blood-2015-09-672030 https://ashpublications.org/blood/article/127/16/2007/34862/The-clinical-significance-of-EBV-DNA-in-the-plasma https://ashpublications.org/blood/article/127/16/2007/34862/The-clinical-significance-of-EBV-DNA-in-the-plasma

KIMURA H , KWONG Y L . EBV viral loads in diagnosis, monitoring, and response assessment [J ] . Front Oncol , 2019 , 9 : 62 . DOI: 10.3389/fonc.2019.00062 http://doi.org/10.3389/fonc.2019.00062 https://www.frontiersin.org/article/10.3389/fonc.2019.00062/full https://www.frontiersin.org/article/10.3389/fonc.2019.00062/full

ALLEN U D , PREIKSAITIS J K , AST INFECTIOUS DISEASES COMMUNITY OF PRACTICE . Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation [J ] . Am J Transplant , 2013 , 13 ( Suppl 4 ): 107 - 120 . DOI: 10.1111/ajt.12104 http://doi.org/10.1111/ajt.12104 https://onlinelibrary.wiley.com/doi/10.1111/ajt.12104 https://onlinelibrary.wiley.com/doi/10.1111/ajt.12104

CAMPO E , SWERDLOW S H , HARRIS N L , et al . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [J ] . Blood , 2011 , 117 ( 19 ): 5019 - 5032 . DOI: 10.1182/blood-2011-01-293050 http://doi.org/10.1182/blood-2011-01-293050 https://ashpublications.org/blood/article/117/19/5019/20991/The-2008-WHO-classification-of-lymphoid-neoplasms https://ashpublications.org/blood/article/117/19/5019/20991/The-2008-WHO-classification-of-lymphoid-neoplasms

RAUSCH L , KOENECKE C , KOCH H F , et al . Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation [J ] . Transplant Res , 2016 , 5 : 6 . DOI: 10.1186/s13737-016-0036-1 http://doi.org/10.1186/s13737-016-0036-1 http://transplantationresearch.biomedcentral.com/articles/10.1186/s13737-016-0036-1 http://transplantationresearch.biomedcentral.com/articles/10.1186/s13737-016-0036-1

刘彦权 , 沈建箴 , 刘庭波 , 等 . 第504例孕32周、贫血—顽固性溶血性贫血—重症肺部感染—心功能不全—左肾占位—弥漫大B细胞淋巴瘤 [J ] . 中华医学杂志 , 2020 , 100 ( 20 ): 1588 - 1592 .

LIU Y Q , SHEN J Z , LIU T B , et al . Case 504, 32 weeks of gestation, anemia-refractory hemolytic anemia-severe pulmonary infection-cardiac dysfunction-left renal mass-diffuse large B-cell lymphoma [J ] . Natl Med J China , 2020 , 100 ( 20 ): 1588 - 1592 .

READY E , CHERNUSHKIN K , PARTOVI N , et al . Posttransplant lymphoproliferative disorder in adults receiving kidney transplantation in British Columbia: a retrospective cohort analysis [J ] . Can J Kidney Health Dis , 2018 , 5 : 2054358118760831.

TAOKA K , NANNYA Y , YAMAMOTO G , et al . Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer [J ] . Am J Hematol , 2009 , 84 ( 9 ): 600 - 603 . DOI: 10.1002/ajh.21479 http://doi.org/10.1002/ajh.21479 https://onlinelibrary.wiley.com/doi/10.1002/ajh.21479 https://onlinelibrary.wiley.com/doi/10.1002/ajh.21479

AFSHAR K , RAO A P , PATEL V , et al . Use of foscarnet therapy for EBV infection following control of PTLD with enhancement of cellular immunity in a lung-transplant recipient [J ] . J Transplant , 2011 , 2011 : 919651.

HÖCKER B , BÖHM S , FICKENSCHER H , et al . (Val-) Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation [J ] . Transpl Int , 2012 , 25 ( 7 ): 723 - 731 . DOI: 10.1111/j.1432-2277.2012.01485.x http://doi.org/10.1111/j.1432-2277.2012.01485.x https://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2012.01485.x https://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2012.01485.x

PETERS A C , AKINWUMI M S , CERVERA C , et al . The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience [J ] . Transplantation , 2018 , 102 ( 9 ): 1553 - 1562 . DOI: 10.1097/TP.0000000000002146 http://doi.org/10.1097/TP.0000000000002146 https://journals.lww.com/00007890-201809000-00031 https://journals.lww.com/00007890-201809000-00031

PARKER A , BOWLES K , BRADLEY J A , et al . Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS guidelines [J ] . Br J Haematol , 2010 , 149 ( 5 ): 693 - 705 . DOI: 10.1111/j.1365-2141.2010.08160.x http://doi.org/10.1111/j.1365-2141.2010.08160.x https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08160.x https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08160.x

TSAI D E , HARDY C L , TOMASZEWSKI J E , et al . Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients [J ] . Transplantation , 2001 , 71 ( 8 ): 1076 - 1088 . DOI: 10.1097/00007890-200104270-00012 http://doi.org/10.1097/00007890-200104270-00012 http://journals.lww.com/00007890-200104270-00012 http://journals.lww.com/00007890-200104270-00012

GHOBRIAL I M , HABERMANN T M , RISTOW K M , et al . Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era [J ] . Leuk Lymphoma , 2005 , 46 ( 2 ): 191 - 196 . DOI: 10.1080/10428190400012011 http://doi.org/10.1080/10428190400012011 https://www.tandfonline.com/doi/full/10.1080/10428190400012011 https://www.tandfonline.com/doi/full/10.1080/10428190400012011

CHOQUET S , LEBLOND V , HERBRECHT R , et al . Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study [J ] . Blood , 2006 , 107 ( 8 ): 3053 - 3057 . DOI: 10.1182/blood-2005-01-0377 http://doi.org/10.1182/blood-2005-01-0377 http://www.bloodjournal.org/cgi/doi/10.1182/blood-2005-01-0377 http://www.bloodjournal.org/cgi/doi/10.1182/blood-2005-01-0377

BISHNOI R , BAJWA R , FRANKE A J , et al . Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients [J ] . Exp Hematol Oncol , 2017 , 6 : 26 . DOI: 10.1186/s40164-017-0087-0 http://doi.org/10.1186/s40164-017-0087-0 https://doi.org/10.1186/s40164-017-0087-0 https://doi.org/10.1186/s40164-017-0087-0

TRAPPE R U , DIERICKX D , ZIMMERMANN H , et al . Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase Ⅱ trial [J ] . J Clin Oncol , 2017 , 35 ( 5 ): 536 - 543 .

TRAPPE R , OERTEL S , LEBLOND V , et al . Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial [J ] . Lancet Oncol , 2012 , 13 ( 2 ): 196 - 206 . DOI: 10.1016/S1470-2045(11)70300-X http://doi.org/10.1016/S1470-2045(11)70300-X https://linkinghub.elsevier.com/retrieve/pii/S147020451170300X https://linkinghub.elsevier.com/retrieve/pii/S147020451170300X

MYNAREK M , SCHOBER T , BEHRENDS U , et al . Posttransplant lymphoproliferative disease after pediatric solid organ transplantation [J ] . Clin Dev Immunol , 2013 , 2013 : 814973.

GROSS T G , ORJUELA M A , PERKINS S L , et al . Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a children’s oncology group report [J ] . Am J Transplant , 2012 , 12 ( 11 ): 3069 - 3075 . DOI: 10.1111/j.1600-6143.2012.04206.x http://doi.org/10.1111/j.1600-6143.2012.04206.x https://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2012.04206.x https://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2012.04206.x

浏览量

1315

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

良、恶性卵巢甲状腺肿临床病理分析

SMARCA4缺失型肺恶性肿瘤的临床病理学特征及患者预后分析

87例唾液腺导管癌患者的治疗策略与预后分析：一项回顾性队列研究

放射性淋巴细胞减少对局限期小细胞肺癌患者预后的影响：一项队列研究

肢端型黑色素瘤组织中MITF的表达及其与临床、病理学特征及预后的相关性研究